文献速递中医内科中药与中成药合理使用

咽宁糖浆通过调节肠道菌群、短链脂肪酸及CD4+T细胞平衡改善LPS诱导的大鼠炎症

Yanning Syrup ameliorates the lipopolysaccharide-induced inflammation: Adjusting the gut microbiota, short-chain fatty acids, and the CD4+ T cell balance.
PubMed 文献 · J Ethnopharmacol · 2021-10-08

本研究以腹腔注射LPS(8 mg/kg)诱导炎症大鼠模型,探讨咽宁糖浆对肠道菌群失调及CD4+T细胞免疫稳态的作用。结果显示咽宁糖浆降低死亡率与组织学评分,增加结肠IL-17A、IL-4、IL-10及血清多种细胞因子,恢复Th17/Treg与Th1/Th2平衡,提高菌群多样性并增加短链脂肪酸产生。

要点

  • 咽宁糖浆可减轻LPS诱导的大鼠结肠炎症,降低死亡率和组织学评分。
  • 咽宁糖浆恢复MLNs、血和BALF中Th17/Treg平衡及MLNs和全血Th1/Th2平衡。
  • 咽宁糖浆增加肠道菌群多样性及乙酸、丁酸、戊酸、己酸等短链脂肪酸产生。

核心结论

  • 咽宁糖浆通过调节肠道菌群、增加菌群来源短链脂肪酸及平衡Th1/Th2与Treg/Th17细胞,改善LPS诱导的大鼠炎症。

研究设计与样本

  • 采用腹腔注射LPS(8 mg/kg)诱导炎症大鼠模型,观察咽宁糖浆的干预效果。
  • 通过H&E染色观察组织学变化,16S rRNA基因测序和靶向代谢组学分析肠道菌群与短链脂肪酸。
  • 采用Luminex细胞因子微阵列和ELISA检测血清与结肠细胞因子,流式细胞术表型分析MLNs、BALF和全血中Th1、Th2、Th17和Treg细胞频率。

主要发现

  • 咽宁糖浆治疗组大鼠结肠炎症减轻,表现为死亡率和组织学评分降低。
  • 咽宁糖浆上调结肠组织IL-17A、IL-4、IL-10水平,并升高血清IL-1α、IL-5、IL-7、IL-12(p70)、GM-CSF和VEGF水平。
  • 咽宁糖浆调节MLNs、血和BALF中Th17与Treg细胞数量,恢复Th17/Treg平衡,并恢复MLNs和全血中Th1/Th2平衡。
  • 16S rRNA测序显示咽宁糖浆增加肠道菌群多样性,抑制Enterobacter和Blautia等有害菌,增加Firmicutes和Actinobacteria。
  • 靶向代谢组学显示咽宁糖浆增加乙酸、丁酸、戊酸和己酸的产生,且受调控的优势菌属与短链脂肪酸及炎症因子浓度相关。

临床怎么用

  • 咽宁糖浆在LPS诱导炎症大鼠中展现抗炎与免疫调节作用,其机制涉及肠道菌群-短链脂肪酸-CD4+T细胞轴。
  • 临床用于急性上呼吸道感染和急性肠炎时,可关注其对肠道微生态及Th1/Th2、Th17/Treg平衡的潜在调节价值。

局限性

  • 本研究仅在大鼠模型中验证,样本量未在摘要中报告,临床外推需谨慎。
  • 咽宁糖浆多成分的具体药效物质基础及直接作用靶点尚未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: As a commercial Chinese patent medicine, Yanning Syrup (YN) is used to treat acute upper respiratory tract infections and acute enteritis effectively in clinical practice. However, the underlying mechanism remains unclear. AIMS OF THE STUDY: To reveal the effect of YN on gut microbiota dysbiosis, and explore the potential role of the gut microecosystem and CD4+ T cell immune homeostasis in YN-treated respiratory and intestinal diseases in lipopolysaccharide (LPS)-induced inflammatory rats. METHODS: Inflammation in rat models was induced by intraperitoneal injection of LPS (8 mg/kg). Histological changes were observed by H & E staining. Changes in gut microbiota and short-chain fatty acid (SCFA) production were analysed using 16S rRNA gene sequencing and targeted metabolomics. A Luminex cytokine microarray and enzyme-linked immunosorbent assay (ELISA) were conducted to evaluate the serum and colon cytokine profiles. The frequencies of immune cells, including Th1, Th2, Th17 and Treg cells in the mesenteric lymph nodes (MLNs), bronchoalveolar lavage fluid (BALF) and whole blood were phenotyped using flow cytometry. RESULTS: The YN-treated rats showed less colon inflammation, as evidenced by the reduction in mortality rate and histology score. Notably, YN was found to improve the immunosuppressed state induced by LPS in rats, which not only upregulated the levels of the proinflammatory cytokine IL-17A and the immunosuppressive cytokines IL-4 and IL-10 in colon tissue but also increased the levels of IL-1α, IL-5, IL-7, IL-12 (p70), GM-CSF and VEGF in serum. The numbers of Th17 cells and Treg cells in the MLNs, blood, and BALF of model rats were regulated by YN, with the restoration of the Th17/Treg balance. Additionally, the Th1/Th2 balance in MLNs and whole blood of model rats was restored after YN administration. Sequencing of 16S rRNA gene indicated that YN-treated rats exhibited greater gut microbial diversity and flora composition, specifically inhibiting some harmful bacteria such as Enterobacter and Blautia and increasing Firmicutes and Actinobacteria. Targeted metabolomics analysis demonstrated an increase of SCFA (acetic acid, butyric acid, valeric acid, and hexanoic acid) production in YN-treated rats. Most of the dominant bacterial genera regulated by YN administration were correlated with the concentrations of SCFA and inflammatory cytokines. CONCLUSIONS: These results demonstrated that YN could ameliorate LPS-induced inflammation in rats by modifying gut microbiota, increasing microbiota-derived SCFA production and regulating the balance of Th1/Th2 and Treg/Th17 cells.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Wei D, Ma P, Fan Q, et al. Yanning Syrup ameliorates the lipopolysaccharide-induced inflammation: Adjusting the gut microbiota, short-chain fatty acids, and the CD4+ T cell balance. J Ethnopharmacol. 2021. PMID: 34634365. doi:10.1016/j.jep.2021.114729

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。